[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 28, 2003

Analysis of Generic Nevirapine Products in Developing CountriesRESEARCH LETTER

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289(20):2648-2649. doi:10.1001/jama.289.20.2648-c

To the Editor: Combination antiretroviral therapy (CART) can dramatically improve the prognosis of patients with human immunodeficiency virus (HIV), but 90% of infected individuals worldwide do not have access to these drugs.1 Although generic drugs are now available in many countries at costs that are considerably lower than those of discounted proprietary agents, there have been anecdotal reports of generic antiviral medications that contain little or no active ingredients.2,3 As part of a quality-assurance investigation, we analyzed the content of several generic and proprietary antiretroviral formulations containing the non-nucleoside reverse transcriptase inhibitor nevirapine.

First Page Preview View Large
First page PDF preview
First page PDF preview
×